Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) will post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Achieve Life Sciences to post earnings of ($0.26) per share for the quarter. Investors that wish to listen to the company's conference call can do so using this link.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.03). During the same period in the previous year, the company posted ($0.43) EPS. On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Achieve Life Sciences Trading Down 0.6 %
Shares of NASDAQ:ACHV traded down $0.03 during trading on Thursday, reaching $4.70. The company's stock had a trading volume of 89,391 shares, compared to its average volume of 139,828. The firm's 50 day simple moving average is $4.65 and its two-hundred day simple moving average is $4.75. The company has a current ratio of 4.56, a quick ratio of 4.56 and a debt-to-equity ratio of 0.21. Achieve Life Sciences has a 12 month low of $3.03 and a 12 month high of $5.98. The stock has a market capitalization of $161.40 million, a PE ratio of -4.26 and a beta of 1.56.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on ACHV shares. Raymond James assumed coverage on Achieve Life Sciences in a research report on Friday, September 27th. They set a "strong-buy" rating and a $20.00 target price on the stock. Oppenheimer restated an "outperform" rating and issued a $11.00 target price on shares of Achieve Life Sciences in a report on Thursday, August 15th.
Read Our Latest Stock Report on Achieve Life Sciences
About Achieve Life Sciences
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Further Reading
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
